Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
REGULATORY
Should Japan Go Ahead with Off-Year Re-Pricing amid COVID-19 Outbreak? Chuikyo Members Want It Discussed
Members of an all-important reimbursement policy panel on April 8 called for discussions on whether Japan should go ahead with its plan to implement so-called “off-year” re-pricing from next April despite the current unusual circumstances surrounding the novel coronavirus pandemic.…
To read the full story
Related Article
- Industry Says There’s No Way Off-Year Drug Price Survey Can Be Done; Chuikyo Healthcare Reps Agree but Payers Don’t
June 11, 2020
- Chuikyo Wary about Off-Year Price Survey amid COVID-19, Industry Officials Stress Concerns
May 28, 2020
- Blurred Outlook for Off-Year Drug Re-Pricing, Will Japan Go Ahead with April 2021 Plan?
April 27, 2020
- Pharma, Healthcare Circle See “Off-Year” Drug Re-Pricing Unrealistic amid Coronavirus Crisis
March 25, 2020
REGULATORY
- Opposition DPP Leader Pledges to Go Full Throttle on Ending Off-Year Revisions
December 3, 2024
- Qalsody, Zepbound, Zeposia Inch Closer to Japan Approval with Panel OK
December 3, 2024
- LDP Pharma Study Group Renews Call for Ditching Off-Year Revisions
December 3, 2024
- Japan Cabinet OKs Extra Budget, 44 Billion Yen for Pharma Measures
December 2, 2024
- Pharma Industry Makes Plea to Komeito to Scrap Off-Year Revisions
December 2, 2024
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…